Item 2.02 - Results of Operations and Financial Condition: Charles River Laboratories issued a press release on August 5, 2026, providing financial results for the second quarter ended June 27, 2026. Forward-Looking Statements: The press release includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, indicating that certain statements are forward-looking…

Our analysis rates this filing NEUTRAL. The moderate concern level (4.8/10) reflects a balanced picture of near-term headwinds offset by improving underlying demand trends and strategic execution. The company faces three legitimate operational concerns: divestiture-related losses impacting GAAP…

Concern level: ELEVATED (4.8/10). Key factors: Divestiture-related losses of $63.7M ($1.40/share) create material near-term GAAP earnings headwind, requiring GAAP guidance reduction; DSA segment operating margin compression of 180 basis points (27.4% to 25.6%) driven by higher study-related direct costs, though company characterizes as temporary; RMS segment organic revenue decline of 1.4%…

Notable risk changes: Guidance Raised: Company increased 2026 revenue and non-GAAP EPS guidance (organic revenue guidance up 150 bps, non-GAAP EPS up $0.25 at midpoint) driven by improving DSA demand and Manufacturing outperformance - positive signal for demand recovery; Divestiture Losses Disclosed: $63.7M loss ($1.40/share) from CDMO and Cell Solutions divestitures reduces GAAP earnings but reflects strategic…

No analyst consensus data provided in filing.

The model predicts CRL will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.